HOOKIPA Pharma Inc
NASDAQ:HOOK

  • LAST PRICE
    2.1500
  • TODAY'S CHANGE (%)
    -0.1500 (-6.5217%)
  • Bid / Lots
    2.1400/ 1
  • Ask / Lots
    2.1900/ 2
  • Open / Previous Close
    2.3400 / 2.3000
  • Day Range
    2.0800
    2.3800
  • 52 Week Range
    2.0800
    11.3000
  • Volume
    93,992

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
HOOK
HOOKIPA Pharma Inc
27.7M
-0.5x
---
CARA
Cara Therapeutics Inc
17.0M
-0.2x
---
TSBX
Turnstone Biologics Corp
10.9M
-0.1x
---
VDRM
Viaderma Inc
10.7M
0.0x
---
SQZB
SQZ Biotechnologies Co
781.5K
0.0x
---
PRE
Prenetics Global Ltd
54.0M
-1.2x
---
As of 2024-11-23

Company Information

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Contact Information

Headquarters
350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118
Phone
---
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Julie O'Neill
Chief Executive Officer, Director
Malte Peters
Chief Financial Officer, Executive Vice President, Director
Terry Coelho
Chief Operations Officer
Roman Necina
Chief Scientific Officer
Klaus Orlinger

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$27.7M
Revenue (TTM)
$50.0M
Shares Outstanding
12.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.72
EPS
$-4.11
Book Value
$7.45
P/E Ratio
-0.5x
Price/Sales (TTM)
0.6
Price/Cash Flow (TTM)
---
Operating Margin
-121.78%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.